Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2019 from OUS - The Lipid Clinic
15 publications found
Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
Adv Ther, 36 (7), 1786-1811
DOI 10.1007/s12325-019-00985-8, PubMed 31102204
LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia
J Clin Lipidol, 13 (2), 279-286
DOI 10.1016/j.jacl.2019.01.010, PubMed 30910667
Serum Omega-6 Fatty Acids and Immunology-Related Gene Expression in Peripheral Blood Mononuclear Cells: A Cross-Sectional Analysis in Healthy Children
Mol Nutr Food Res, 63 (7), e1800990
DOI 10.1002/mnfr.201800990, PubMed 30702198
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
J Am Coll Cardiol, 74 (17), 2132-2146
DOI 10.1016/j.jacc.2019.08.1024, PubMed 31648705
Lower risk of smoking-related cancer in individuals with familial hypercholesterolemia compared with controls: a prospective matched cohort study
Sci Rep, 9 (1), 19273
DOI 10.1038/s41598-019-55682-x, PubMed 31848411
Impaired HDL Function Amplifies Systemic Inflammation in Common Variable Immunodeficiency
Sci Rep, 9 (1), 9427
DOI 10.1038/s41598-019-45861-1, PubMed 31263122
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
J Clin Endocrinol Metab, 104 (11), 5253-5262
DOI 10.1210/jc.2018-02703, PubMed 31166599
Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia
JAMA Cardiol, 4 (11), 1156-1159
DOI 10.1001/jamacardio.2019.3903, PubMed 31617858
Lipoprotein(a) concentration is associated with plasma arachidonic acid in subjects with familial hypercholesterolaemia
Br J Nutr, 122 (7), 790-799
DOI 10.1017/S0007114519001600, PubMed 31262370
Profiling of immune-related gene expression in children with familial hypercholesterolaemia
J Intern Med, 287 (3), 310-321
DOI 10.1111/joim.13001, PubMed 31631426
Infant cholesterol and glycated haemoglobin concentrations vary widely-Associations with breastfeeding, infant diet and maternal biomarkers
Acta Paediatr, 109 (1), 115-121
DOI 10.1111/apa.14936, PubMed 31299108
Postprandial changes in gene expression of cholesterol influx and efflux mediators after intake of SFA compared with n-6 PUFA in subjects with and without familial hypercholesterolaemia: secondary outcomes of a randomised controlled trial
J Nutr Sci, 8, e27
DOI 10.1017/jns.2019.25, PubMed 31448116
Community pharmacies offer a potential high-yield and convenient arena for total cholesterol and CVD risk screening
Eur J Public Health, 29 (1), 17-23
DOI 10.1093/eurpub/cky190, PubMed 30239673
Milk and Dairy Product Consumption and Inflammatory Biomarkers: An Updated Systematic Review of Randomized Clinical Trials
Adv Nutr, 10 (suppl_2), S239-S250
DOI 10.1093/advances/nmy072, PubMed 31089732
Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects
Atherosclerosis, 287, 140-146
DOI 10.1016/j.atherosclerosis.2019.06.900, PubMed 31280039